AcuraStem proclaimed it has signed a licensing deal with Takeda.

Alvotech revealed that its distribution associate in Japan, Fuji Pharma Co., Ltd., has obtained commercialisation authorization for AVT04 (ustekinumab).

TransCode Therapeutics has reported positive findings with its primary treatment candidate, TTX-MC138, in mouse models with human glioblastoma multiforme tumors.

NMD Pharma A/S has revealed that the initial patient has received their first dose in a Phase II clinical study of the ClC-1 inhibitor NMD670 in individuals affected by spinal muscular atrophy.

Sandoz gains consent from the European Commission for its unique multiple sclerosis biosimilar, Tyruko® (natalizumab) in Europe.

Lantern Pharma Inc. has started Phase 1 clinical trial on its experimental drug, LP-184, for advanced solid tumors. This is part of the company's ongoing clinical drug development.

Escient Pharmaceuticals commences trial-based study of EP262, an innovative, orally-taken MRGPRX2 blocker for chronic inducible hives.

Data provided by Longhorn vaccine and diagnostics indicate that lhnvd-201 has neutralizing activity against covid-19 and influenza coinfection.

Appili Therapeutics a biodefense and infectious disease drug company, announced that its production and marketing partner, Saptalis Pharmaceuticals, received US FDA approval for Metronidazole Oral Suspension 500mg/5mL.

Nova Therapeutics, a biotech firm specializing in Influenza A treatments, received US FDA approval for its IND application for influenza A suppressant, VNT-101.

Merck reported that the phase III KEYNOTE-A39/EV-302 test halted disease progression in certain patients with local or metastatic urothelial cancer who hadn't received prior treatment.

Genmab Unveils EU Commission's Authorization for TEPKINLY® (epcoritamab) to Treat Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in Adults.